Find and Pitch Jounalists, Get Your Story Covered

Tags: Palazestrant Phase 1b/2 Trial Future Trials

	Profile	Recent Articles on Subject
1	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Adding Radioligand to Enzalutamide Boosts OS in Metastatic CRPC - 9 days ago Talazoparib-Enzalutamide Improves Survival in Metastatic CRPC - 10 days ago New First-Line Option for Advanced ALK-Positive Lung Cancer - 2 months ago Palbociclib Regimen Yields 'Incredible' PFS Gain in Metastatic Breast Cancer - 2 months ago FDA Approves Zanidatamab for Biliary Tract Cancer - 3 months ago Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer - 5 months ago Doxorubicin-Trabectedin Strategy Boosts Survival in Challenging Sarcoma - 6 months ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - 6 months ago Perioperative Tislelizumab Demonstrates Survival Benefit in NSCLC - about 1 year ago Cabozantinib Plus Atezolizumab Delays Progression in mCRPC - about 1 year ago Atezolizumab Plus Carboplatin Boosts Survival in Metastatic TNBC - about 1 year ago Novel Drug Makes Its Case for Pretreated Primary Biliary Cholangitis - over 1 year ago Pembrolizumab in First-Line Boosts PFS in HER2-Positive Stomach Cancer - over 1 year ago
2	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Lynparza approved in Scotland for BRCA-mutated breast cancer patients - 12 days ago
3	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Pliant Therapeutics Presses Pause on Clinical Trial for Lung Disorder Drug - 13 days ago
4	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Posdinemab Receives FDA Fast Track Designation for Treatment of Alzheimer Disease - about 2 months ago SABCS 2024: Camizestrant Shows Promise in Combination with Ribociclib for Advanced Breast Cancer - 2 months ago SABCS 2024: Combination of Elacestrant and Abemaciclib Shows Promising Progression-Free Survival in ER+/HER2- Advanced Breast Cancer - 2 months ago Zaltenibart Receives FDA Rare Pediatric Disease Designation for C3 Glomerulopathy - 4 months ago Novel Chemotherapy Method Could Decrease Lung Cancer Tumor Size - 12 months ago FDA Approves Pembrolizumab Plus Chemotherapy to Treat Metastatic HER2-Negative Gastric, Gastroesophageal Junction Adenocarcinoma - over 1 year ago
5	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Approves Tislelizumab in Combination With Chemotherapy for Gastric, Gastrosophageal Junction Adenocarcinoma - about 2 months ago Arrowhead Pharmaceuticals Submits FDA Application for Plozasiran in Familial Chylomicronemia Syndrome - 3 months ago FDA Grants Orphan Drug Designation to PPL-002 for the Treatment of Danon Disease - 5 months ago Exploratory Analysis Shows Favorable Outcomes for Amivantamab-Lazertinib Treatment in NSCLC - 5 months ago FDA Grants Orphan Drug Designation to ZMA001 for Pulmonary Arterial Hypertension - 7 months ago Dostarlimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit in Endometrial Cancer - 11 months ago AstraZeneca to Initiate Trial for Triple-Combination Inhaled Therapy for Chronic Obstructive Pulmonary Disease - 11 months ago FDA Approves Berdazimer Topical Gel as First Treatment for Molluscum Contagiosum - about 1 year ago FDA Approves Belzutifan for Treatment of Advanced Renal Cell Carcinoma - about 1 year ago Belantamab Mafodotin Met Primary Endpoint for Those with Relapsed, Refractory Multiple Myeloma - about 1 year ago Prevention, Treatment for Migraine Rapidly Evolves, Calling for Development of Novel Drugs - over 1 year ago FDA Approves Capivasertib With Fulvestrant for PIK3CA/ALT1/PTEN Alterations Breast Cancer - over 1 year ago Domvanalimab-Containing Regimen Shows Positive Preliminary Data for Upper Gastrointestinal Cancers - over 1 year ago Datopotamab Deruxtecan Demonstrates Improvement in Progression-Free Survival in HR+, HER2- Breast Cancer - over 1 year ago FDA Grants Priority Review to New Drug Application for Belzutifan for Advanced Renal Cell Carcinoma - over 1 year ago
6	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Testing Elacestrant With Other Targeted Drugs for Metastatic Breast Cancer - about 2 months ago Cabozantinib Plus Atezolizumab Improves PFS in Metastatic CRPC - about 1 year ago
7	The Conversation Science Alert Science news. Official account. Australia science news	Ozempic vs Supplements: Dietitian Reveals Truth About GLP-1 Imitations - 3 months ago
8	Sophie Putka MedPage Today Enterprise, investigative writer. New York, USA enterprise journalisminvestigative journalism	Long-Term Data Support Non-Hormonal Drug for Hot-Flash Management - 5 months ago
9	Aislinn Antrim, Assistant Managing Editor Pharmacy Times Journalist at Pharmacy Times. UNC graduate. PoliticsStorytellingCats	FDA Grants Breakthrough Therapy Designation to Plozasiran for Familial Chylomicronemia Syndrome - 6 months ago FDA Experts Review Data, Regulatory Insights for New Metastatic Breast Cancer Therapies - about 1 year ago FDA Experts Review Data, Regulatory Insights for New Metastatic Breast Cancer Treatments - about 1 year ago FDA Approves Zilucoplan for Generalized Myasthenia Gravis in AChR Antibody-Positive Adults - over 1 year ago
10	Erin Hunter, Associate Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	FDA Grants Fast Track Designation to PT886 for the Treatment of Pancreatic Cancer - 11 months ago FDA Approves Expanded Indications for Spesolimab-sbzo Injection for the Treatment of Generalized Pustular Psoriasis - 11 months ago Risankizumab Demonstrated Superior to Apremilast for Patients With Moderate Psoriasis - 12 months ago

Journalists covering Palazestrant